{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:45:04Z","timestamp":1790232304758,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Disorders of glucose metabolism are a serious acromegaly comorbidity and may be differently impacted by medical treatments of acromegaly. In this retrospective longitudinal multicenter study, we investigated the outcome of glucose metabolism and its predictors in patients treated with Pasireotide LAR (PAS-LAR) alone or in combination with Pegvisomant (PAS-LAR\u2009+\u2009Peg-V).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects and methods<\/jats:title>\n                <jats:p>Acromegaly patients treated continously with PAS-LAR or PAS-LAR\u2009+\u2009Peg-V for at least 6 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty patients (25 females, 15 males) were enrolled. At last visit, 27\/40 patients (67.5%) reached biochemical control of acromegaly. Overall, glucose metabolism improved in 3 (all in PAS-LAR\u2009+\u2009Peg-V; 7.5%), worsened in 26 (65%) and remained unchanged in 11 patients (27.5%). Glucose metabolism worsened in 25 patients (73.5%) treated with PAS-LAR and in a single patient (16.7%) treated with PAS-LAR\u2009+\u2009Peg-V (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Among patients treated with Pas-LAR alone, GH at baseline was higher in those with worsening of glucose metabolism (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) as compared to those with stable glucose status. A significantly higher reduction of HbA1c was observed in patients treated with PAS-LAR\u2009+\u2009Peg-V, as compared with those treated with PAS-LAR alone (<jats:italic>p<\/jats:italic>\u2009=\u20090.005).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data confirmed that glucose metabolism in patients treated with PAS-LAR is often worsened, and may be predicted by entity of baseline GH hypersecretion and by the dose of PAS-LAR. Moreover, our data, although limited by small numbers, may suggest that the combination treatment PAS-LAR\u2009+\u2009Peg-V can improve glucose homeostasis in selected patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-021-02711-3","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T18:04:28Z","timestamp":1619546668000},"page":"658-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant"],"prefix":"10.1007","volume":"73","author":[{"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Donfrancesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara M.","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mirra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"2711_CR1","doi-asserted-by":"publisher","unstructured":"Melmed, S. Pituitary-tumor endocrinopathies. N Engl J Med. (2020). https:\/\/doi.org\/10.1056\/NEJMra1810772","DOI":"10.1056\/NEJMra1810772"},{"key":"2711_CR2","doi-asserted-by":"publisher","unstructured":"Gadelha, M.R., Kasuki, L., Lim, D.S.T., Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. (2019). https:\/\/doi.org\/10.1210\/er.2018-00115","DOI":"10.1210\/er.2018-00115"},{"key":"2711_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.wneu.2019.03.049","volume":"127","author":"D Solari","year":"2019","unstructured":"D. Solari, R. Pivonello, C. Caggiano, E. Guadagno, C. Chiaramonte, G. Miccoli, L.M. Cavallo, M. Del Basso De Caro, A. Colao, P. Cappabianca, Pituitary adenomas: what are the key features? what are the current treatments? where is the future taking us? World Neurosurg. 127, 695\u2013709 (2019)","journal-title":"World Neurosurg."},{"key":"2711_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1055\/a-1020-3992","volume":"51","author":"S\u00c7 Altunta\u015f","year":"2019","unstructured":"S.\u00c7. Altunta\u015f, M. Evran, M. Sert, T. Tetiker, Markers of metabolic syndrome in patients with pituitary adenoma: a case series of 303 patients. Horm Metab Res. 51, 709\u201313 (2019)","journal-title":"Horm Metab Res."},{"key":"2711_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1530\/eje.0.1510439","volume":"151","author":"A Mestron","year":"2004","unstructured":"A. Mestron, S.M. Webb, R. Astorga, P. Benito, M. Catala, S. Gaztambide, J. Gomez, I. Halperin, T.M. Morante, B. Moreno, G. Obiols, P. de Pablos, C. Paramo, A. Pico, E. Torres, C. Varela, J.A. Vazquez, J. Zamora, M. Albareda, M. Gilabert, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espa\u00f1ol de Acromegalia, REA). Eur J Endocrinol. 151, 439\u201346 (2004)","journal-title":"Eur J Endocrinol."},{"key":"2711_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1530\/EJE-10-1050","volume":"164","author":"S Fieffe","year":"2011","unstructured":"S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer,, Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol. 164, 877\u201384 (2011)","journal-title":"Eur J Endocrinol."},{"key":"2711_CR7","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1210\/jc.2016-1937","volume":"101","author":"LA Portocarrero-Ortiz","year":"2016","unstructured":"L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. Garc\u00eda-Dominguez, A.A. Reza-Albarr\u00e1n, D. Cuevas-Ramos, V. Melgar, J. Talavera, A. de Jesus Rivera-Hernandez, C.V. Valencia-M\u00e9ndez, M. Mercado; Mexican Acromegaly Registry Group, The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 101, 3997\u20134004 (2016)","journal-title":"J Clin Endocrinol Metab."},{"key":"2711_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/ERC-17-0253","volume":"24","author":"P Petrossians","year":"2017","unstructured":"P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah, R. Auriemma, A.M. Diallo, A.L. Hulting, D. Ferone, V. Hana, S. Filipponi, C. Sievers, C. Nogueira, C. Fajardo-Monta\u00f1ana, D. Carvalho, V. Hana, G.K. Stalla, M.J. Jaffrain-R\u00e9a, B. Delemer, A. Colao, T. Brue, S.J.C.M.M. Neggers, S. Zacharieva, P. Chanson, A. Beckers, P. Petrossians, A.F. Daly, E. Natchev, Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database. Endocr. Relat. Cancer 24, 505\u201318 (2017)","journal-title":"Endocr. Relat. Cancer"},{"key":"2711_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1530\/EJE-12-0084","volume":"167","author":"M Arosio","year":"2012","unstructured":"M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis, R. Pivonello, S. Grottoli, M. Losa, S. Cannav\u00f2, F. Minuto, M. Montini, M. Bondanelli, E. De Menis, C. Martini, G. Angeletti, A. Velardo, A. Peri, M. Faustini-Fustini, P. Tita, F. Pigliaru, G. Borretta, C. Scaroni, N. Bazzoni, A. Bianchi, M. Appetecchia, F. Cavagnini, G. Lombardi, E. Ghigo, P. Beck-Peccoz, A. Colao, M. Terzolo,Italian Study Group of Acromegaly, Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 167, 189\u201398 (2012)","journal-title":"Eur J Endocrinol."},{"key":"2711_CR10","doi-asserted-by":"publisher","unstructured":"Espinosa-de-los-Monteros A.L., Gonz\u00e1lez B., Vargas G., Sosa E., Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary. (2011). https:\/\/doi.org\/10.1007\/s11102-010-0284-x","DOI":"10.1007\/s11102-010-0284-x"},{"key":"2711_CR11","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"T. Feola, A. Cozzolino, I. Simonelli, E. Sbardella, C. Pozza, E. Giannetta, D. Gianfrilli, P. Pasqualetti, A. Lenzi, A.M. Isidori, Glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 104, 2892\u2013902 (2019)","journal-title":"J Clin Endocrinol Metab."},{"key":"2711_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/EJE-13-0032","volume":"169","author":"C Urbani","year":"2013","unstructured":"C. Urbani, C. Sardella, A. Calevro, G. Rossi, I. Scattina, M. Lombardi, I. Lupi, L. Manetti, E. Martino, F. Bogazzi, Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 169, 99\u2013108 (2013)","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2711_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.-C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Res\u00e9ndiz, M. Ruffin, Y. Chen, M. Sheppard,on behalf of the Pasireotide C2305 Study Group, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 99(3), 791\u2013799 (2014)","journal-title":"J Clin Endocrinol Metab."},{"key":"2711_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"M.R. Gadelha, M.D. Bronstein, T. Brue, M. Coculescu, M. Fleseriu, M. Guitelman, V. Pronin, G. Raverot, I. Shimon, K.K. Lievre, J. Fleck, M. Aout, A.M. Pedroncelli, A. Colao,Pasireotide C2402 Study Group, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2, 875\u201384 (2014)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2711_CR15","doi-asserted-by":"publisher","unstructured":"Petersenn, S., Schopohl, J., Barkan, A., Mohideenet, P., Colao, A., Abs, R., Buchelt, A., Ho, Y.Y., Hu, K., Farrall, A.J., Melmed, S., Biller, B.M.K. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. (2010). https:\/\/doi.org\/10.1210\/jc.2009-2272","DOI":"10.1210\/jc.2009-2272"},{"key":"2711_CR16","doi-asserted-by":"publisher","unstructured":"Colao, A., Auriemma, R.S., Lombardi, G., Pivonello, R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. (2011). https:\/\/doi.org\/10.1210\/er.2010-0002","DOI":"10.1210\/er.2010-0002"},{"key":"2711_CR17","doi-asserted-by":"publisher","unstructured":"Gola, M., Bonadonna, S., Mazziotti, G., Amato, G., Giustina, A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest. (2006). https:\/\/doi.org\/10.1007\/BF03349183","DOI":"10.1007\/BF03349183"},{"issue":"7","key":"2711_CR18","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed,Acromegaly Consensus Group, A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 95(7), 3141\u20133148 (2010)","journal-title":"J Clin Endocrinol Metab."},{"key":"2711_CR19","doi-asserted-by":"publisher","unstructured":"Giustina, A., Barkhoudarian, G., Beckers, A., Ben-Shlomo, A., Biermasz, N., Biller, B., Boguszewski, C., Bolanowski, M., Bollerslev, J., Bonert, V., Bronstein, M.D., Buchfelder, M., Casanueva, F., Chanson, P., Clemmons, D., Fleseriu, M., Formenti, A.M., Freda, P., Gadelha, M., Geer, E., Gurnell, M., Heaney, A.,.P., Ho, K.K.Y., Ioachimescu, A.G., Lamberts, S., Laws, E., Losa, M., Maffei, P., Mamelak, A., Mercado, M., Molitch, M., Mortini, P., Pereira, A.M., Petersenn, S., Post, K., Puig-Domingo, M., Salvatori, R., Samson, S.L., Shimon, I., Strasburger, C., Swearingen, B., Trainer, P., Vance, M.L., Wass, J., Wierman, M.E., Yuen, K.C.J., Zatelli, M.C., Melmed, S. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. (2020). https:\/\/doi.org\/10.1007\/s11154-020-09588-z","DOI":"10.1007\/s11154-020-09588-z"},{"key":"2711_CR20","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. (2020). https:\/\/doi.org\/10.2337\/dc20-S002","DOI":"10.2337\/dc20-S002"},{"key":"2711_CR21","doi-asserted-by":"publisher","unstructured":"Fleseriu, M., Biller, B.M.K., Freda, P.U., Gadelha, M.R., Giustina, A., Katznelson, L., Molitch, M.E., Samson, S.L., Strasburger, C.J., van der Lely, A.J., Melmed, S. A Pituitary Society update to acromegaly management guidelines. Pituitary. (2020). https:\/\/doi.org\/10.1007\/s11102-020-01091-7","DOI":"10.1007\/s11102-020-01091-7"},{"key":"2711_CR22","doi-asserted-by":"publisher","unstructured":"Giustina, A., Barkan, A., Beckers, A., Biermasz, N., Biller, B.M.K., Boguszewski, C., Bolanowski, M., Bonert, V., Bronstein, M.D., Casanueva, F.F., Clemmons, D., Colao, A., Ferone, D., Fleseriu, M., Frara, S., Gadelha, M.R., Ghigo, E., Gurnell, M., Heaney, A.P., Ho, K., Ioachimescu, A., Katznelson, L., Kelestimur, F., Kopchick, J., Krsek, M., Lamberts, S., Losa, M., Luger, A., Maffei, P., Marazuela, M., Mazziotti, G., Mercado, M., Mortini, P., Neggers, S., Pereira, A.M., Petersenn, S., Puig-Domingo, M., Salvatori, R., Shimon, I., Strasburger, C., Tsagarakis, S., van der Lely, A.J., Wass, J., Zatelli, M.C., Melmed, S. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz096","DOI":"10.1210\/clinem\/dgz096"},{"key":"2711_CR23","doi-asserted-by":"publisher","unstructured":"Mazziotti, G., Floriani, I., Bonadonna, S., Torri, V., Chanson, P., Giustina, A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. Clin Endocrinol Metab. (2009) https:\/\/doi.org\/10.1210\/jc.2008-2332","DOI":"10.1210\/jc.2008-2332"},{"key":"2711_CR24","doi-asserted-by":"publisher","unstructured":"Schmid, H.A., Brue, T., Colao, A., Gadelha, M.R., Shimon, I., Kapur, K., Pedroncelli, A.M., Fleseriu, M. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. (2016). https:\/\/doi.org\/10.1007\/s12020-016-0895-8","DOI":"10.1007\/s12020-016-0895-8"},{"key":"2711_CR25","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1007\/s12020-016-1029-z","volume":"54","author":"A Luger","year":"2016","unstructured":"A. Luger, Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment. Endocrine. 54, 0\u20131 (2016)","journal-title":"Endocrine."},{"key":"2711_CR26","doi-asserted-by":"publisher","unstructured":"Giustina, A. Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol Metab. (2020). https:\/\/doi.org\/10.1016\/j.tem.2020.01.011","DOI":"10.1016\/j.tem.2020.01.011"},{"key":"2711_CR27","doi-asserted-by":"publisher","unstructured":"Chiloiro, S., Giampietro, A., Frara, S., Bima, C., Donfrancesco, F., Fleseriu, C.M., Pontecorvi, A., Giustina, A., Fleseriu, M., De Marinis, L., Bianchi A. Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J Clin Endocrinol Metab. (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz054","DOI":"10.1210\/clinem\/dgz054"},{"key":"2711_CR28","doi-asserted-by":"publisher","unstructured":"Chiloiro, S., Mazziotti, G., Giampietro, A., Bianchi, A., Frara, S., Mormando, M., Pontecorvi, A., Giustina, A., De Marinis, L. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary. (2018). https:\/\/doi.org\/10.1007\/s11102-018-0873-7","DOI":"10.1007\/s11102-018-0873-7"},{"key":"2711_CR29","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab. 27, 470\u201383 (2016)","journal-title":"Trends Endocrinol Metab."},{"key":"2711_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ghir.2009.09.002","volume":"20","author":"A Vijayakumar","year":"2010","unstructured":"A. Vijayakumar, R. Novosyadlyy, Y.J. Wu, S. Yakar, D. LeRoith, Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm. IGF Res. 20, 1\u20137 (2010)","journal-title":"Growth Horm. IGF Res."},{"key":"2711_CR31","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/BF00873216","volume":"29","author":"S Karlander","year":"1986","unstructured":"S. Karlander, M. Vrani\u0107, S. Efendi\u0107, Increased glucose turnover and glucose cycling in acromegalic patients with normal glucose tolerance. Diabetologia. 29, 778\u201383 (1986)","journal-title":"Diabetologia."},{"key":"2711_CR32","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/db06-0299","volume":"56","author":"JP del Rincon","year":"2007","unstructured":"J.P. del Rincon, K. Iida, B.D. Gaylinn, C.E. McCurdy, J.W. Leitner, L.A. Barbour, J.J. Kopchick, J.E. Friedman, B. Draznin, M.O. Thorner, Growth hormone regulation of p85 expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes. 56, 1638\u201346 (2007)","journal-title":"Diabetes."},{"key":"2711_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1210\/er.2008-0027","volume":"30","author":"N M\u00f8ller","year":"2009","unstructured":"N. M\u00f8ller, J.O.L. J\u00f8rgensen, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 30, 152\u201377 (2009)","journal-title":"Endocr Rev."},{"key":"2711_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1210\/mend-3-1-165","volume":"3","author":"JH Nielsen","year":"1989","unstructured":"J.H. Nielsen, S. Linde, B.S. Welinder, N. Billestrup, O.D. Madsen, Growth hormone is a growth factor for the differentiated pancreatic \u03b2-cell. Mol Endocrinol. 3, 165\u201373 (1989)","journal-title":"Mol Endocrinol."},{"key":"2711_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11102-013-0471-7","volume":"17","author":"O Alexopoulou","year":"2014","unstructured":"O. Alexopoulou, M. Bex, P. Kamenicky, A.B. Mvoula, P. Chanson, D. Maiter, Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 17, 81\u201389 (2014)","journal-title":"Pituitary."},{"key":"2711_CR36","doi-asserted-by":"publisher","unstructured":"Vila, G., J\u00f8rgensen, J.O.L., Luger, A., Stalla, G.K. Insulin resistance in patients with acromegaly. Front Endocrinol. (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00509","DOI":"10.3389\/fendo.2019.00509"},{"key":"2711_CR37","first-page":"717","volume":"19","author":"A Giustina","year":"1998","unstructured":"A. Giustina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 19, 717\u201397 (1998)","journal-title":"Endocr Rev."},{"issue":"3","key":"2711_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1530\/EJE-10-0811.","volume":"164","author":"G Mazziotti","year":"2011","unstructured":"G. Mazziotti, T. Porcelli, F. Bogazzi, G. Bugari, S. Cannav\u00f2, A. Colao, R. Cozzi, L. De Marinis, E. degli Uberti, S. Grottoli, F. Minuto, M. Montini, M. Spinello, A. Giustina, Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol. 164(3), 341\u20137 (2011). https:\/\/doi.org\/10.1530\/EJE-10-0811.","journal-title":"Eur J Endocrinol."},{"key":"2711_CR39","doi-asserted-by":"publisher","unstructured":"Chiloiro, S., Giampietro, A., Mirra, F., Donfrancesco, F., Tartaglione, T., Mattogno, P.P., Angelini, F., Lauretti, L., Gessi, M., Anile, C., Rindi, G., Giustina, A., Fleseriu, M., Pontecorvi, A., De Marinis, L., Bianchi, A. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response. Eur J Endocrinol. (2020). https:\/\/doi.org\/10.1530\/EJE-20-0767","DOI":"10.1530\/EJE-20-0767"},{"key":"2711_CR40","doi-asserted-by":"publisher","unstructured":"Coopmans, E.C., Korevaar, T.I.M., van Meyel, S.W.F., Daly, A.F., Chanson, P., Brue, T., Delemer, B., H\u00e1na, V., Colao, A., Carvalho, D., Jaffrain-Rea, M.L., Stalla, G.K., Fajardo-Monta\u00f1ana, C., Beckers, A., van der Lely, A.J., Petrossians, P., Neggers, S.J.C.M.M. Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab. (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa387","DOI":"10.1210\/clinem\/dgaa387"},{"key":"2711_CR41","doi-asserted-by":"publisher","unstructured":"Chiloiro, S., Bima, C., Tartaglione, T., Giampietro, A., Gessi, M., Lauretti, L., Anile, C., Colosimo, C., Rindi, G., Pontecorvi, A., De Marinis, L., Bianchi, A. Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study. J Clin Endocrinol Metab. (2019) https:\/\/doi.org\/10.1210\/jc.2019-00825.","DOI":"10.1210\/jc.2019-00825"},{"key":"2711_CR42","doi-asserted-by":"publisher","unstructured":"Muhammad, A., Coopmans, E.C., Delhanty, P.J.D., Dallenga, A.H.G., Haitsma, I.K., Janssen, J.A.M.J.L., van der Lely, A.J., Neggers, S.J.C.M.M. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol. (2018). https:\/\/doi.org\/10.1530\/EJE-18-0353","DOI":"10.1530\/EJE-18-0353"},{"issue":"6","key":"2711_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40618-017-0614-1.","volume":"40","author":"A Giustina","year":"2017","unstructured":"A. Giustina, G. Arnaldi, F. Bogazzi, S. Cannav\u00f2, A. Colao, L. De Marinis, E. De Menis, E. Degli Uberti, F. Giorgino, S. Grottoli, A.G. Lania, P. Maffei, R. Pivonello, E. Ghigo, Pegvisomant in acromegaly: an update. J Endocrinol Invest 40(6), 577\u2013589 (2017). https:\/\/doi.org\/10.1007\/s40618-017-0614-1.","journal-title":"J Endocrinol Invest"},{"key":"2711_CR44","doi-asserted-by":"publisher","unstructured":"Ciresi, A., Radellini, S., Guarnotta, V., Giordano, C. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report. BMC Endocr Disord. (2018). https:\/\/doi.org\/10.1186\/s12902-018-0231-9","DOI":"10.1186\/s12902-018-0231-9"},{"key":"2711_CR45","doi-asserted-by":"publisher","unstructured":"Melmed, S., Bronstein, M.D., Chanson, P., Klibanski, A., Casanueva, F.F., Wass, J.A.H., Strasburger, C.J., Luger, A., Clemmons, D.R., Giustina, A. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. (2018). https:\/\/doi.org\/10.1038\/s41574-018-0058-5.","DOI":"10.1038\/s41574-018-0058-5"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02711-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02711-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T09:20:45Z","timestamp":1627723245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02711-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02711-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MF reports serving as an investigator with research grants to OHSU for Crinetics, Chiasma, Ionis, Novartis, Recordati; and serving as an occasional consultant to Crinetics, Chiasma, Ipsen, Novartis, Pfizer, Recordati. ORCID: 0000-0001-9284-6289, AG: Research Grants from Ipsen, Novartis and Pfizer. Consultant for Genevant and Ipsen. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"(Institutional Review Board approval was received).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"(a waiver of subject consent was approved).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"(all authors approve the submission).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}